CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,579 enrolled
Drug / intervention
Aspirin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03023020
NCT03023020N/ACompleted
CompareCT.gov

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

ECRI bv·interventional·Posted Jan 18, 2017·Updated Aug 20, 2021

In Brief

A clinical study evaluating Aspirin and P2Y12 inhibitor for High Bleeding Risk and 2 related conditions. Completed, enrolled 4,579 participants across 138 sites in 30 countries.

Detailed Summary

The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with a drug covered stent (metallic tube). This comparison will be done in patients who, compared to the average patient, are more likely to suffer from complications on antiplatelet therapy (bleeding). Both durations are within the current medical recommendations. The aim of this study is to help improve further standard antiplatelet duration guidelines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHigh Bleeding Risk, Coronary Artery Disease, PCI
CountriesArgentina, Australia, Austria, Bahrain, Bangladesh, Belgium, Bulgaria, Czechia, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Japan, Netherlands, North Macedonia, Poland, Saudi Arabia, Serbia, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, United Kingdom, Vietnam
CollaboratorsCardialysis B.V., European Cardiovascular Research Center, University of Bern, Terumo Medical Corporation

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 18, 2017
Enrollment StartApr 4, 2017
Primary CompletionApr 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 9.5 years ago

Interventions

Aspirindrug

Dosing per current guidelines and local practice

P2Y12 inhibitordrug

Dosing per current guidelines and local practice